News & Media

ImmunoQure enables the establishment of Sardinian patient support group

ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today welcomed the establishment of a non-profit charity for APS-1/APECED patients who live in Sardinia.

ImmunoQure AG announces publication of findings that advance it’s Interferon program in the journal Arthritis & Rheumatology

ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the journal Arthritis & Rheumatology.

ImmunoQure AG announces publication in leading scientific journal of findings that enable companion diagnostic development for Interferon program

ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal The Journal of Experimental Medicine. In a Worlds-first, the authors have developed a system by which interferon-α (IFNα) levels can be measured in serum, plasma and cerebrospinal fluid.